The global autoimmune treatment market size is estimated to be USD 4,831 million in 2021 and is expected to witness a CAGR of 11.7% during the forecast period. Rising global incidence of autoimmune diseases is a key driver for the growth of the global autoimmune treatment market. Additionally, increase in investments by government and private players for research and development in autoimmune disease treatment and growth in the developments of diagnostic procedures are some of the other drivers propelling the market growth. However, low coverage in medical insurance for autoimmune diseases and lack of knowledge regarding the treatment of autoimmune diseases among developing economies are expected to restrain the global market growth.

By Indication

Based on indication, the market is categorized as diabetes, inflammatory bowel disease, rheumatic disease, multiple sclerosis, and other indications. In 2021, the rheumatic disease segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This can be attributed to rise in incidence of rheumatic diseases along with the growth in patient awareness worldwide. Multiple sclerosis segment is projected to grow at a profitable CAGR during the forecast period. This can be attributed to the surge in the number of Patient Assistance Orograms (PAPs) and increase in number of pipeline drugs for the treatment of this disease.

By Drug Class

Based on drug class, the market is segmented into anti-hyperglycemics, anti-inflammatory, interferons, NSAIDs, and other drugs. In 2021, the anti-inflammatory segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This can be attributed to the increasing demand for anti-inflammatory drugs, introduction of novel anti-inflammatory drugs coupled with helpful reimbursement policies worldwide. Anti-hyperglycemics segment is expected to grow at a profitable CAGR during the forecast period. This can be attributed to the increasing application of this segment in the treatment of diabetes as this drug type is used for lowering glucose levels in diabetic patient.

By Distribution

Based on distribution, the market is categorized into online, hospital pharmacy, and others. In 2021, the online segment accounted for a substantial revenue share and is anticipated to grow with a lucrative CAGR during the forecast period. This is due to preference for online purchase due to convenience, especially for physically challenged, old aged, and working professionals worldwide. The hospital pharmacy segment is anticipated to grow at a profitable CAGR during the forecast period due to the hospital pharmacy assisting in minimizing dispensing errors and rising number of hospital pharmacies.

Regional Insights

In 2021, North America holds the highest revenue segment in the global market and is expected to maintain its dominance during the forecast period. This can be attributed to the availability of high disposable income, incidence of a large patient pool suffering from various types of autoimmune disorders, growth in initiatives from the government, accessibility of technologically advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to less stringent regulations, growing government and corporate investment in healthcare sector, increasing travel tourism in the developing economies, and growth in healthcare expenditure in the per capita income.

Competitor Insights

Some of the key players in the autoimmune treatment market are AbbVie (U.S.); Amgen Inc. (U.S.); Johnson & Johnson (U.S.); Eli Lilly and Company (U.S.); Pfizer, Inc. (U.S.); F. Hoffmann-La Roche AG (Switzerland); Astrazeneca Plc (U.K.); Bristol-Myers Squibb Co. (U.S.); Lupin Limited (India); and GlaxoSmithKline Plc (U.K.). The leading players operating in the autoimmune treatment industry are adopting various strategies including R&D investments, adaption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The autoimmune treatment market report is categorized into the following segments and subsegments:

Autoimmune Treatment Market, By Indication (Revenue, USD Million, 2021 – 2029)

Autoimmune Treatment Market, By Drug Class (Revenue, USD Million, 2021 – 2029)

Autoimmune Treatment Market, By Distribution (Revenue, USD Million, 2021 – 2029)

Autoimmune Treatment Market, By Region (Revenue, USD Million, 2021 – 2029)

Scope of Autoimmune Treatment Market Report:

Key Parameters	Details
Base Year	2021
Forecast Period	2022-2029
Study Coverage	Global and regional market size and revenue forecast Segment market size and revenue forecast at global, regional, and country level Competitive landscape (company share analysis, company profiles, recent development, competitive map analysis) Conclusion and recommendations
Qualitative Analysis	Market drivers Market restraints Market opportunities Recent market trends Market challenges Porter’s Five Forces analysis PEST analysis Value-chain analysis COVID-19 impact analysis
Regional Market Scope	North America (U.S. and Canada) Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe) Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC) Latin America (Brazil, Mexico, Argentina, Rest of LATAM) MEA (South Africa, GCC, Rest of MEA)
Company Profiles	Exhaustive profiles of top 15 players 50+ other major players listing
15% Free Customization Available	You can customize the study scope to meet your exact requirement. Click here for more details